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This article reviews the literature related to the main idea of the study, rooting from the definition of 
biotechnology, global status of commercialized biotechnology products, and global and local public 
attitudes towards modern biotechnology and past models for attitude towards modern biotechnology. 
The first section of the review will be the in-depth-discussion regarding the definition of modern 
biotechnology according to several established international organizations, followed by global status of 
commercialized biotechnology products which will emphasize on how modern biotechnology is 
classified and which area are being focused more by the stakeholders, and global and local public 
attitudes towards modern biotechnology based on previous studies. Last but not least, the final section 
is credited to past studies related to attitudes and past models of public attitudes towards 
biotechnology, both globally and locally. A developing country like Malaysia was chosen in this article 
as an example of the case study related to local situation of modern biotechnology.  
 





United Nations on biological diversity defines biotechno-
logy as any technological application that incorporates 
biological system, living organisms, or derivatives thereof, 
to produce or to refine products or processes for specific 
use (United Nations, 1992). It is acknowledged that 
biotechnology has formed the fundamental of knowledge 
about people and diseases, and that includes supporting 
various developments of treatments (Biotechnology 
Online). Even though the term biotechnology started to 
bloom up when a Hungarian agricultural engineer, Karl 




*Corresponding author. E-mail: nilam@ukm.my. Tel: +603-
89216907. Fax: +603-89252976. 
 
Abbreviations: GMO, Genetically modified organism; NRC, 
National Research Council; CIHR, Canadian Institute for Health 
Research; GM, genetically modified. 
ancient and classical biotechnology techniques have 
been documented to exist over centuries ago. For 
examples, the use of moldy soybean curds by the 
Chinese as an antibiotic in order to treat boils exist since 
500 B.C, the manipulation of plant traits through selective 
breeding in order to improve the crops yield, and the use 
of microorganisms in fermentation to make bread and 
wine (Biotechnology Institute). 
According to Department of Primary Industries of 
Victoria state (Australia), modern biotechnology is 
another stage that comes after ancient and classical 
biotechnology, which describes a range of processes and 
techniques particularly involved at the molecular level, 
and that includes genomics, genetic modification (gene 
technology, genetic engineering), molecular marker-
assisted breeding, cloning, bioprocessing and cell cul-
ture. However, it is always noted that the terms modern 
biotechnology and genetic engineering can be used in 
the current context interchangeably since most establish- 
 




ed regulations agree that both fields do not involve 
traditional breeding and mutagenesis (Latifah et al., 
2007). The product resulted from modern biotechnology 
or genetic engineering processes is called genetically 
modified organism (GMO). Study has shown that GMO 
can increase the crops' yield while reducing the number 
of applications of insecticides (Qaim et al., 2003). 
 
 
GLOBAL STATUS OF COMMERCIALIZED 
BIOTECHNOLOGY PRODUCTS 
 
Nowadays, Biotechnology has been classified into 
few categories based on their applications. 
 
1. Bioinformatics: Interdisciplinary field that involves 
solving biological puzzles using computer applica-
tions, organizing and analyzing biological data 
(Luscombe et al., 2001). 
2. Red biotechnology: Biotechnology used in medical 
processes, to produce antibiotics, or to provide 
genetic cures through genomic manipulation (Lorenz 
et al., 2005).  
3. Green biotechnology: Biotechnology used in 
agricultural processes, such as to grow food crops 
with enhanced nutritional content, or to increase their 
yields (Lorenz et al., 2005). 
4. Blue biotechnology: Biotechnology used in marine 
and aquatic organisms, as to increase seafood 
supply and safety, controlling the proliferation of 
deadly water-borne organisms, bioremediation, and 
developing new drugs (Biology Online). 
5. White biotechnology: Biotechnology used in industrial 
processes, to produce chemicals, materials and 
energy source (Lorenz et al., 2005). 
 
Red Biotechnology is currently leading the modern 
biotechnology industry, followed by green biotechnology, 
each of which are focusing on biopharmaceuticals and 
GM crops, respectively (Latifah et al., 2007). Since, the 
approval of the first biopharmaceuticals product in 1982, 
which was the recombinant human insulin, the pharma-
ceutical industry has grown rapidly, producing some 140 
biopharmaceuticals by the year 2003 (Walsh, 2004). The 
first generation of biopharmaceuticals were targeted 
towards a variety of widespread diseases such as 
diabetes, growth disorders, genetic disorders, infertility, 
infectious diseases, blood disorders, cancer, autoimmune 
disorders, heart diseases, AIDs, skin disorders, non-
malignant tumor, and hypoglycemia (Walsh, 2004). Since 
then, Red biotechnology continues to promote innovation 
in order to create novel biopharmaceuticals, to reduce 
current product's production cost and to improve current 
product’s therapeutic value. For example, National 
Research Council (NRC) of Canada coordinates policies, 
budgets, and strategies for innovation in biotechnology as 
part of the government aim to drive Canada as one of the 





2008). Canadian government’s main health research 
funding agency, The Canadian Institute for Health 
Research (CIHR), had allocated $699 million as their 
budget between 2005 and 2006 (Rosenberg-Yunger et 
al., 2008). 
Transgenic tobacco was among the first genetically 
modified (GM) crops to be commercialized as an 
outcome of the emergence of green biotechnology (Jan-
Peter et al., 2003). This began unofficially in China in 
1992, it was then followed by commercial planting of GM 
FLAVR SAVR™ tomato by the USA in 1994 (Jan-Peter et 
al., 2003). Since then, commercial large scale plantings 
of GM crops started to increase steadily, with a growth of 
more than 10% per year, beginning at 1.7 hectares in 
1996 to 58.7 million hectares in 2002 (James, 2002). 
Following the commercial approval of the GM tomato, few 
transgenic crops were being approved and entered the 
global market one by one. Currently, GM rice (Bt rice) and 
GM maize (biotech phytase maize) had been approved 
by China on 27 November 2009 (James, 2009). These 
approvals are momentous and have enormous implica-
tions for biotech crop adoption not only for China and 
Asia, but for the whole world since rice is the most 
important food crop in the world and maize is the major 
animal feed crop in the world (James, 2009). Prior to the 
approval, in October 2009, a landmark decision was 
made by India’s Genetic Engineering Approval Commi-
ttee (GEAC) to recommend the commercial release of 
GM Brinjal (Bt brinjal/eggplant) in India. However, the 
final decision regarding the matter is still pending and 
subject to the final clearance by the government of India 
(James, 2009). Besides, other transgenic crops which 
have been commercialized until 2010 are GM soybean, 
maize, cotton, canola, squash, papaya, alfalfa, sugarbeet, 
tomato, poplar, and sweet pepper (James, 2010). 
Yet, the global GM area had increased to a total of 67.7 
million hectares in 2003 (James, 2003) before reaching 
more than a twofold increase – 148 million hectares in 
2010 (Table 1, James, 2010). The number of countries 
growing transgenic crops has increased steadily from 6 in 
1996 to 18 in 2003 and 29 in 2010 (James, 2010). The 
principal crops in 2010 remained the same as in 2003, 
with GM soybean continued to be the leading principal 
GM crop occupying 73.3 million hectares or 50% of global 
biotech area, followed by GM maize which occupies 46.8 
million hectares (31%), GM cotton which occupies 21 
million hectares (14%) and GM canola occupying 7.0 
million hectares (5%) (James 2003, 2010). Consistently, 
the dominant trait during the fifteen-year period 1996 to 
2010 was herbicide tolerance (James, 2010). 
“Gene stacking” or “gene pyramiding” is a term to 
describe a breeding approach to attain higher crop yield 
while controlling the pest at the same time (Taverniers et 
al., 2008). It is a prominent way for researchers to trans-
fer multiple traits to a crop, usually involving insect 
resistance and herbicide resistance. Until 2010, 11 coun-
tries have already planted the crops containing stacked 
genes, occupying up to 22% of global  biotech  crop  area 




Table 1. Global area of transgenic crops in 2010 by country. 
 
Country Hectare (million) Hectare (%) Biotech Crop 
USA 66.8 45.1 Soybean, maize, cotton, canola, squash, papaya, alfalfa, sugarbeet 
Brazil 25.4 17.2 Soybean, maize, cotton 
Argentina 22.9 15.5 Soybean, maize, cotton 
India 9.4 6.4 Cotton 
Canada 8.8 6.0 Canola, maize, soybean, sugarbeet 
China 3.5 2.4 Cotton, tomato, poplar, papaya, sweet pepper 
Paraguay 2.6 1.8 Soybean 
Pakistan 2.4 1.6 Cotton 
South Africa 2.2 1.5 Maize, soybean, cotton 
Uruguay 1.1 <1 Soybean, maize 
Bolivia 0.9 <1 Soybean 
Australia 0.7 <1 Cotton, canola 
Philippines 0.5 <1 Maize 
Myanmar 0.3 <1 Cotton 
Burkina Faso 0.3 <1 Cotton 
Spain 0.1 <1 Maize 
Mexico 0.1 <1 Cotton, soybean 
Colombia <0.1 <1 Cotton 
Chile <0.1 <1 Maize, soybean, canola 
Honduras <0.1 <1 Maize 
Portugal <0.1 <1 Maize 
Czech Republic <0.1 <1 Maize, potato 
Poland <0.1 <1 Maize 
Egypt <0.1 <1 Maize 
Slovakia <0.1 <1 Maize 
Costa Rica <0.1 <1 Cotton, soybean 
Romania <0.1 <1 Maize 
Sweden <0.1 <1 Potato 
Germany <0.1 <1 Potato 
TOTAL 148 100  
 




(Table 2). More of the two-third of maize planted in the 
USA contain stacked genes. One of the stacked maize 
variant, known as “SmartstaxTM” which has eight genes 
in it coding for several pest resistant and herbicide 
tolerant traits was released in the USA and Canada in the 
same year (James, 2010). 
Among nations, blue biotechnology is mostly at various 
developmental stages. Taken Norway as an example, 
several new initiatives promise to discover novel 
enzymes, drugs, and other helpful compounds, along with 
the exploration of the marine ecosystem's genetic 
diversity. For example, various species of sponge have 
been collected which filter million liters of water every 
day; they are claimed to cove bacteria and work as anti-
infective (anti-bacterial) (Aldridge, 2005). Ellingsen, who 
is a research director at SINTEF (Foundation for 
Scientific and Industrial Research at the Norwegian 
Institute of Technology), added that they have already 
found the production organisms for all the products and it 
is the time now to screen those for industrial potential 
(Aldridge, 2005). In addition, the latest finding of soluble 
beta glucan (SBG), an immunostimulant derived from 
used in fish feed to decrease mortality (Aldridge, 2005) 
could potentially contribute significant impact on blue 
biotechnology industry. 
White biotechnology has been valued as the most 
reliable solution in order to produce alternative energy 
sources for the future. Most stakeholders agreed that 
sooner or latter white biotechnology will lead the industry 
through their biomass based product which will eventually 
assist the petroleum-dependent economies (Lorenz et al., 
2005). This renewable energy approach has been pro-
posed as a new transportation fuel due to an increment of 
conventional energy cost and global warming concerns 
(Yarris, 2010). Furthermore, recent study has shown that 
Escherichia coli bacteria is capable to produce biodiesel 
fuel and other important chemicals derived from energy-
rich  molecules   such   as   fatty   acids.   Department   of   




Table 2. Global area of GM crops in 2010. 
 
Trait Crop Area (million hectares) Area (%) 
Herbicide tolerance Soybean, maize, canola, cotton, sugarbeet and alfalfa  89.3 61 
Stacked double and triple traits  Maize, cotton 32.3 22 
Insect resistance Maize, cotton 26.3 17 
Total  148 100 
 




Energy's Joint BioEnergy Institute (JBEI) has been 
looking into the possibility of converting biomass directly 
to biodiesel using the E. coli strain that has been 
engineered (Yarris, 2010). 
 
 
MODERN BIOTECHNOLOGY STATUS IN MALAYSIA 
 
Malaysia aims to use biotechnology as an economic 
growth vehicle by the year 2020 (Firdaus-Raih et al., 
2005; BIOTEK, 2010) by introducing the Malaysian 
Biotechnology Policy which is divided into three phases - 
Phase I (2005-2010), Phase II (2010-2015), and Phase III 
(2016-2020) (MABIC, 2010). The first phase, accom-
plished in 2010, consists of research and development (R 
and D), technology development, and promotion of 
biotechnology programs (BIOTEK, 2010). During this 
period, the government had taken a promotion step by 
actively introducing biotechnology into the classrooms of 
high schools throughout the nation (Firdaus-Raih et al., 
2005), established BiotechCorp (Malaysian Biotechno-
logy Corporation) as the primary center for biotechnology 
industry development in this country, provided various 
fiscal and tax incentives to biotechnology companies 
granted the BioNexus status (BIOTEK, 2010), and 
introduced several grants which are ScienceFund, 
Technofund, Innofund, e-Content and DAGS Roll Out in 
order to support the studies and local projects financially, 
from R and D to commercialization stage (MOSTI, 2010). 
In Malaysia, the exact boundary between conventional 
and modern biotechnology has not been established. As 
long as the study involved any biotechnology techniques 
or tools, they are included under biotechnology (Latifah et 
al., 2007). Among research organizations in Malaysia 
which engage with the first R and D stage are: 
 
1. Malaysian Agricultural Research and Development 
Institute (MARDI). 
2. Malaysian Palm Oil Board (MPOB). 
3. Rubber Research Institute, Malaysia (RRIM). 
4. Institute of Medical Research (IMR). 
5. Universiti Kebangsaan Malaysia (UKM). 
6. Universiti Malaysia Sarawak (UNIMAS). 
7. Universiti Putra Malaysia (UPM). 
8. Universiti Sains Malaysia (USM). 
9. Universiti Malaya (UM). 
10. Univeristi Teknologi Malaysia (UTM). 
11. Standard Institution for Industry Malaysia (SIRIM). 
12. Malaysian Institution for Nuclear Technology (MINT). 
13. Forest Research Institute of Malaysia (FRIM). 
14. Veterinary Research Institution (VRI). 
 
Being an agriculture-based nation, the strength of 
Biotechnology in Malaysia is in agricultural biotechnology 
(green biotechnology) which is foreseen as a potential 
powerful tool to ensure food security and to boost the 
country's economy (Latifah et al., 2007). Even though 
modern biotechnology products developed by Malaysian 
researchers were not being planted and commercialized 
yet, but the action is almost there. One of the researches 
focused on the development of delayed ripening papaya, 
which has already been approved by the Genetic 
Modification Advisory Committee (GMAC) for contained 
field trials (Latifah et al., 2010). In fact other GM products 
from other countries are slowly coming into the country. In 
2004, the only agricultural product available in the 
Malaysian market is Glyphosate resistant soybean 
(Latifah et al., 2007). However, it is no doubt that GM 
maize has already entered the market since YieldGard™ 
maize, RoundupReady™ maize and YieldGard™ maize 
(all released by Monsanto) has already been approved 
for imports into the country (Hoh, 2010). 
Espicom (2008) estimates that the Malaysian biophar-
maceutical market would be at US$75 million in 2008 and 
believes it will rise to US$132 million by year 2013. At 
least twenty six biopharmaceuticals products of modern 
biotechnology techniques were already registered with 
the Ministry of Health of Malaysia for use in this country 
(Latifah et al., 2007). The therapeutic values of the 
biopharmaceutical products range from different types of 
insulin for the treatment of diabetes, growth hormones, 
drug for the treatment of various kinds of cancers, 
hepatitis, infertility, autoimmune disorders, organ 
transplant and infectious diseases (Latifah et al., 2007). 
The first biopharmaceutical plant was opened in Nilai, 
Negri Sembilan in June 2006. Fully owned by a local 
biotechnology firm Inno Biologics Sdn Bhd, which encom-
passes gene cloning and expression in CHO cells and 
novel cell expression systems, bioprocess development, 
and cGMP biopharmaceutical manufacturing (Potera, 
2010), the plant will help the country to save up to 30% 
on biogenerics-based drugs in addition to capitalize the 
fact that global industry players are now looking to Asia to 





The phase II of the National Biotechnology Policy has 
been initialized since 2010, and the plan emphasizes on 
the business aspects, such as developing expertise in 
drug discovery and the development based on natural 
resources, new product development, and technology 
acquisition and licensing. Following the Phase II, the 
Phase III will be based on the results achieved in the first 
two phases, and together bringing the local biotechnology 
companies to international status (MABIC, 2010). 
On the contrary, the policy makers themselves, who are 
the backbone of the Malaysian Biotechnology Policy as 
they are responsible in setting the policy framework for 
the government, are quite positive towards the develop-
ment of modern biotechnology in Malaysia. A study by 
communication researchers from ISAAA and the 
University of Illinois at Urbana-Champaign (2003) 
showed that Malaysia's policy makers have some 
willingness to focus on an array of different applications 
of biotechnology ranging from medical, agricultural and 
environmental modern biotechnology applications. In 
addition, majority of the policy makers along with one-
third of the customers involved in the closed ended 
questionnaire showed some level of disagreement in 
contributing time and money to ban GM foods (ISAAA-
UIUC, 2003). The comparison of attitudes towards 
modern biotechnology across Malaysian stakeholders 
based on the previous study will be discussed again in 




GLOBAL PUBLIC ACCEPTANCE TOWARDS MODERN 
BIOTECHNOLOGY 
 
During the first commercial introduction of GM foods 
(crops) in the United States of America (USA), only few 
number of farmers were willing to take the risk that GM 
crops would be marketable (Oeschger and Silva, 2007). 
However, since then, the US farmers began to realize the 
potential of the GM crops in exploiting the global 
agricultural economy. The commercial large scale 
plantings of GM crops started to increase steadily, with a 
growth of more than 10% per year, beginning at 1.7 
hectares in 1996 to 58.7 million hectares in 2002 (James, 
2002). 
Asians were found to be less concerned about medical 
products of genetic engineering compared to genetically 
modified food (Macer et al., 2000). In contrast to the 
European public, the American public is ignorant of GM 
technology and its level of implementation (Oeschger, 
2007). Cynical attitudes to certain applications of gene 
technology seem to be more common in Europe (Siegrist, 
2003) than in the USA, where public is still relatively little 
concerned about gene technology (Loureiro and Hine, 
2004). The uncertainty about possible long-term effects of 
GM food to the environment and human health seems to 
influence the European public who question  the  benefits  




of the new technology between producers and 
consumers (Christoph et al., 2008). The highest degree 
of supports of the Europeans was only restricted to 
genetic testing followed by the introduction of human 
genes into bacteria to produce medicines or vaccines 
(Gaskell et al., 2000). Later, Sjöberg (2008) in his paper 
defined the GM technology as 'a technology that is not 
well received by the European public'. It was found that 
GM technology was rated as the worst of 18 technologies 
by members of the public and highly replaceable, though 
the experts might have a very different view but still saw 
GM technology as replaceable. This clearly demonstrates 
that GM technology was rated as very risky amongst 
Europeans (Sjöberg, 2008). 
The emergence of modern biotechnology in the deve-
loping continent like Africa centers on the development of 
GM crops (GM foods) to fight food insecurity, poverty and 
malnutrition (FAO, 2003), nevertheless the acceptance of 
modern biotechnology there, taking Ghana as an 
example are still between average to low, which could be 
reflected by the level of knowledge of the public (Buah, 
2011). In fact, public who concerned regarding GM 
products in Ghana believed GM will only benefit the big 
multinational companies together with the lack of their 
trust towards the government (Quaye et al., 2009). 
 
 
MALAYSIAN PUBLIC ATTITUDE TOWARDS MODERN 
BIOTECHNOLOGY 
 
Generally, Malaysian stakeholders in the Klang Valley 
region were cautious on modern biotechnology applica-
tions and products (Latifah, 2007). It has been the matter 
of controversial in both modern and developing countries, 
including Malaysia, though its development has been 
rapidly evolved in the past few decades. Organisation for 
Economic Co-operation and Development (OECD) 
(1999) headlines that, worries towards GMO fall under 
three categories: Human health concerns, environmental 
concerns, and ethical concerns, which do not lie on the 
characteristics of the product but rather the way it is 
made. 
As mentioned earlier in this paper, the Malaysian policy 
makers are quite positive towards the development of 
modern biotechnology in Malaysia. They were also 
shown to have high support for GM palm oil; however, 
they were only shown to have moderate encouragement 
for GM soybean and GM insulin (Latifah, 2007). This 
might be due to the fact that oil palm is the primary crop 
production in Malaysia (Shuit et al., 2009) and any of its 
development which helps to drive Malaysia’s economy to 
another level must be fully supported. ISAAA-UIUC 
(2003) has also been reporting that ethical together with 
religious concerns are the main stakeholders’ predomi-
nance on judgments about biotechnology, whereas 
political issues are the least influence on their judgments. 
As a matter of fact there are few “Don’t Know” responses  




to certain statements in the survey conducted, indicating 
that the public were not aware with its status in the 
country or do not posses enough knowledge regarding 
modern biotechnology (ISAAA-UIUC, 2003). Overall, the 
most frequently used sources of information on 
biotechnology by Malaysian stakeholders are the mass 
media (radio, television, and newspapers), followed by 
the printed media and surrounding people, including 
family and friends (ISAAA-UIUC, 2003; Latifah et al., 
2007). This is contradicting with other public/stakeholders 
in other developing country like Ghana. The Ghanaian do 
not use both electronic and printed media solely as 
sources of information on GM foods, instead friends have 
been a major source of information of the matter (Buah, 
2011). 
Few years back, the attitude of the Klang Valley public 
towards modern biotechnology had been assessed using 
certain key variables for specific attitude, including per-
ceived benefits, perceived risks, encouragement or 
overall attitude, moral concerns, familiarity and risk 
acceptance. Generally, the results from the study suggest 
that knowledge and engagement towards biotechnology 
differed across religions, races, ages and education 
levels, but not across gender, while awareness level 
differed across ages, education levels and gender, but 
not across religions and races (Latifah, 2007). Overall, 
the mean scores for encouragement in this study are 
more or less higher than the ISAAA-UIUC report on 
general attitude towards agricultural biotechnology. The 
media were the most critical compared to other 
stakeholder groups as they perceived the highest risk of 
all three surveyed applications (Latifah, 2007). Moreover, 
two issues of modern biotechnology that has intentionally 
been used by the journalists are “GM crops will be so 
resistant to pests and diseases but will push native plants 
into extinction”, and “GM crops will contaminate native 
plant biodiversity” (ISAAA-UIUC, 2003). 
Those with higher levels of education tended to have 
better biotechnology knowledge. Scientists, including 
biotechnologists and biologists, policy makers and 
biology students were in this category. They also scored 
the highest mean in term of familiarity with the biotech-
nology applications (Latifah et al., 2007). Religious 
attachment seemed to influence the Klang Valley public 
towards modern biotechnology applications, with the 
Malays were shown to be the most attached to religion 
followed by the Indian and Chinese. Buddhist experts 
along with those who posses higher levels of education 
had higher biotechnology knowledge. Even though the 
Muslims were found to have least knowledge and less 
engaged with biotechnology, they were found to be the 
most positive towards the promise of modern biotech-
nology. Furthermore, the Muslims and the Hindus showed 
more confidence on the scientists, industries and 
government compared to the Buddhists and Christians 
(Latifah et al., 2007). 





familiarity with the biotechnology applications (GM 
Soybean, Palm Oil, and Insulin); the Chinese seemed to 
have higher biotechnology knowledge than the Indians 
and Malays based on the carried Post Hoc tests (Latifah 
et al., 2007). Chinese community in Klang Valley were 
also the most positive towards the impact of technology, 
and they were also more inclined towards nature and 
professed to have less materialistic values than the 
Malays and the Indians. Meanwhile, the Malays seemed 
to be less engaged with modern biotechnology compared 
to the Chinese and Indians (Latifah et al., 2007). Among 
the three biotechnology products/applications being 
surveyed, GM soybean was regarded as the most risky 
followed by GM insulin and GM palm oil which was 
perceived as having the highest benefits by the Klang 
Valley stakeholders compared to the other two. Finally, all 
biotechnology applications were perceived as having 
moderate encouragement by the respondents from all 
races, from all age groups and from all category of 
education (Latifah et al., 2007). 
 
 
FACTORS INFLUENCING PUBLIC ATTITUDE AND 
ACCEPTANCE OF MODERN BIOTECHNOLOGY 
 
There are many ways to assess the public perception 
towards certain technology. Lim et al. (2009) highlighted 
six major groups of barriers between the technology and 
the public (agreement, knowledge, technology, economic, 
social and political) (Figure 1). These categories which 
collectively referred to as the ‘AKTESP’ barriers are 
adopted from 'Trudgill’s Framework for Analysis' which 
was published in 1990 (Lim et al., 2009). Each stage is 
constantly being questioned whether it hinder the overall 
progress towards the solution. Among these categories, 
only four were almost similar to attitude variables in 
Latifah's framework (2007), agreement, knowledge, 
technology, and social, while economic and political point 
of view were not being stressed in the study. 
Moreover, Lim (2009) used the support from the 
government in terms of providing incentives as well as 
enforcing the use of renewable energy as the benchmark 
to assess the political barriers between the technology 
and the public (Lim et al., 2009). This is parallel with the 
current global situation, where low-cost and environ-
mentally sustainable supplies of food and biofuels will 
depend on significant R and D investment in agriculture, 
nevertheless agricultural research has not been 
underlined in recent years as a spending priority of 
governments (Graff et al., 2009). However, Trudgill’s 
Framework is not suitable in studying the public percep-
tion towards modern biotechnology as earlier researches 
have recommended that public attitude towards a 
complex emerging issue such as modern biotechnology 
should be seen as a multi-dimensional construct (Latifah 
et al., 2007). Dissimilar with Gaskel (2000) who identified 
four   single-directed   dimensions,   Latifah  et  al.  (2007) 






Figure 1: The AKTESP groups of barriers in Trudgill’s 






Figure 2. Model for attitude towards modern biotechnology by the Malaysian. Source: Latifah et al., 2007. 






Figure 3. Conceptual model for attitude towards genetic modification by the Germans. Source: 




developed a multi-dimensions and multi-items instrument, 
which is more applicable in measuring Malaysian public 
attitude towards modern biotechnology (Figure 2). 
Christoph et al. (2008) almost used a similar model 
representing a deeper look at attitudes influencing 
aspects using univariate, bivariate and multivariate 
methods in assessing the attitudes and the acceptability 
of the Germans towards genetic modification. The 
acceptability of genetic modification in different areas of 
application was thought to be linked from the attitudes, 
which is influenced by the following factors, such as, 
socio-demographic variables, knowledge about genetics 
and biotechnology, and the perception of personal health 





Malaysia accomplished their first stage of biotechnology 
policy consisting of research and development (R and D), 
technology development, and promotion of biotechnology 
programs. Among those five areas of modern biotechno-
logy, the green biotechnology (Agricultural biotechnology) 
has been pinpointed by the Malaysia government as the 
focus subject of modern biotechnology in the country. 
After all, it has been perceived as risky by certain public 
and the government has to consider this situation 
circumspectly before approving or developing any 
modern biotechnology applications or products.  
Earlier studies had shown the acceptability of a GM 
products or applications is affected by the public or 
consumer attitudes towards it. It is always important to 
look at the possible attitudes which influence the public 
perception in order to fully understand the multi-faceted 
process related to modern biotechnology acceptance. 
Among the key variables used in previous studies for 
specific attitude are, perceived benefits, perceived risks, 
encouragement, moral concerns, familiarity, and risk 
acceptance, while several general attitudinal factors 
found to be related to specific public attitude included 
general promise and concerns, confidence in key actors, 
impact of technology, societal values, attachment to 
religion, socio demographic factors, knowledge, new age 
beliefs, suspiciousness, politics, worldviews, the effect of 
labeling, awareness and engagement with modern 
biotechnology. The inclusion of these factors would refine 
the existing conceptual model in assessing the Malaysian 
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